JP2002527387A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527387A5
JP2002527387A5 JP2000575500A JP2000575500A JP2002527387A5 JP 2002527387 A5 JP2002527387 A5 JP 2002527387A5 JP 2000575500 A JP2000575500 A JP 2000575500A JP 2000575500 A JP2000575500 A JP 2000575500A JP 2002527387 A5 JP2002527387 A5 JP 2002527387A5
Authority
JP
Japan
Prior art keywords
ara
use according
dha
ratio
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000575500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/007834 external-priority patent/WO2000021524A1/en
Publication of JP2002527387A publication Critical patent/JP2002527387A/ja
Publication of JP2002527387A5 publication Critical patent/JP2002527387A5/ja
Pending legal-status Critical Current

Links

JP2000575500A 1998-10-15 1999-10-15 Ｐｕｆａサプリメント Pending JP2002527387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98308403.9 1998-10-15
EP98308403 1998-10-15
PCT/EP1999/007834 WO2000021524A1 (en) 1998-10-15 1999-10-15 Pufa supplements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010268487A Division JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Publications (2)

Publication Number Publication Date
JP2002527387A JP2002527387A (ja) 2002-08-27
JP2002527387A5 true JP2002527387A5 (enExample) 2006-12-07

Family

ID=8235104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000575500A Pending JP2002527387A (ja) 1998-10-15 1999-10-15 Ｐｕｆａサプリメント
JP2010268487A Pending JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010268487A Pending JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Country Status (13)

Country Link
US (2) US20070184090A1 (enExample)
EP (4) EP2308486A1 (enExample)
JP (2) JP2002527387A (enExample)
CN (3) CN1326344A (enExample)
AT (1) ATE361066T1 (enExample)
AU (2) AU775421B2 (enExample)
CA (2) CA2653503A1 (enExample)
DE (1) DE69935995T3 (enExample)
DK (1) DK1121115T4 (enExample)
ES (1) ES2284286T5 (enExample)
HK (1) HK1042441A1 (enExample)
NZ (1) NZ511071A (enExample)
WO (1) WO2000021524A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156860B2 (en) 2011-04-26 2024-12-03 Biojiva Llc Disorders implicating PUFA oxidation

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
DK1911837T3 (da) 2000-09-28 2011-08-29 Bioriginal Food & Science Corp FAD5-2 fedtsyredesaturasefamiliemedlem og anvendelser deraf
CA2442692A1 (en) * 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU778384B2 (en) * 2001-11-14 2004-12-02 Virtus Nutrition Llc Method for manufacturing fatty acid calcium salts from high glyceride content oils
KR102254453B1 (ko) * 2002-06-19 2021-05-21 디에스엠 아이피 어셋츠 비.브이. 미생물 세포와 미생물 오일용 파스퇴르살균 방법
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
US20070037885A1 (en) * 2003-04-25 2007-02-15 Sandra Edwards Biomass containing animal feed
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
EA200602014A1 (ru) 2004-04-30 2007-08-31 ВИРТУС НЬЮТРИШН ЭлЭлСи Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот
JP5667737B2 (ja) * 2004-07-01 2015-02-12 ネステク ソシエテ アノニム イヌ変形性関節症食餌製剤
ES2253089B1 (es) * 2004-07-16 2007-08-16 Berthol Victor Laboratorios Ordesa, S.L. Complemento nutraceutico para la preparacion de leches infantiles.
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
US20090202672A1 (en) * 2008-02-11 2009-08-13 Monsanto Company Aquaculture feed, products, and methods comprising beneficial fatty acids
CN101259101B (zh) * 2008-04-17 2010-06-02 湖北福星生物科技有限公司 微米级花生四烯酸和二十二碳六烯酸乳状液及其制备方法
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
EP2745706A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Methods for maintaining bone quality
BR112016014262B1 (pt) 2013-12-20 2022-04-05 MARA Renewables Corporation Método para recuperar lipídeos de uma população de micro-organismos
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
IL297000A (en) 2020-04-03 2022-12-01 Mara Renewables Corp Microbial oils with high levels of omega-3 fatty acids
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
WO2024050589A1 (en) * 2022-09-07 2024-03-14 Nourish Ingredients Pty Ltd Compositions and methods for producing meat-like aromas
WO2026020071A1 (en) * 2024-07-18 2026-01-22 Red Abbey Labs, Llc Autogenous therapeutic lipid carriers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
US5658767A (en) † 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1992012711A1 (en) * 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
JPH0692848A (ja) * 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
JPH06271464A (ja) * 1993-03-19 1994-09-27 Tokiwa Yakuhin Kogyo Kk 消化器系障害の予防または治療用アラキドン酸含有組成物
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
JPH07267856A (ja) * 1994-02-09 1995-10-17 Green Cross Corp:The 経口免疫抑制剤
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
DK0969728T4 (da) 1996-03-26 2012-11-19 Dsm Ip Assets Bv Sen tilsætning af PUFA ved fremstillingsproces for formulering til spædbørn
ES2177966T3 (es) 1996-03-26 2002-12-16 Dsm Nv Particulas de vehiculos solidos revestidas con acidos grasos poliinsaturados (pufa) para productos alimentarios.
JP2000508888A (ja) 1996-03-28 2000-07-18 ヒスト―ブロカデス・ベスローテン・フェンノートシャップ 低温殺菌したバイオマスからの微生物多不飽和脂肪酸含有オイルの調製
CA2579516A1 (en) 1996-03-28 1997-10-09 Hendrik Louis Bijl Process for the preparation of a granular microbial biomass and isolation of valuable compounds therefrom
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156860B2 (en) 2011-04-26 2024-12-03 Biojiva Llc Disorders implicating PUFA oxidation

Similar Documents

Publication Publication Date Title
WO2002011564A3 (en) Supplement for type 2 diabetes or lipodystrophy
Sorenson 6 copper complexes offer a physiological approach to treatment of chronic diseases
JPH11199496A5 (enExample)
CA2355341A1 (en) The use of ara as a supplement for a lactating woman
CA2279791C (en) Dietary supplement combining colostrum and lactorferrin in a mucosal delivery format
CA2294099A1 (en) Absorption of minerals
USD458006S1 (en) Body suits
CA2373801A1 (en) Gelled nutritional composition and process
MX2009001156A (es) Composiciones de vitamina d y metodo de administracion a un ser humano.
JPS58501676A (ja) 微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用
WO2001028526A3 (en) Gastroresistant tablets for alimentary, dietetic and therapeutic use
CA2285552A1 (en) Solid compositions suitable for oral administration comprising an alkanoyl-l-carnitine magnesium citrate
JP2003517456A5 (enExample)
USD417933S (en) Combined knee and elbow pads
BG104286A (en) Composition for the suppression of the symptoms of withdrawal and irresistible desire for alcohol in alcoholics and prevention of alcohol addiction among healthy patients
JP2002515439A5 (enExample)
US20130034630A1 (en) Reload energy gel for athletes and active adults
DE60318550D1 (de) Muttermilchzusatz
US6372264B1 (en) Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
Rauf et al. A comprehensive review on nutritional, functional, and clinical perspectives of chia seeds and chia mucilage
NZ505933A (en) Incorporation of cholesterol lowering agents into confectionery dosage forms
Gittleman Super Nutrition for Menopause: Take Control of Your Life and Enjoy New Vitality
CN100387137C (zh) 一种微米花果山金猴子糖消食益胃豆奶粉制备方法
CN2369500Y (zh) 增强男子性功能的保健内裤
CN100387144C (zh) 一种微米金苡白药松花粉消食健脾豆浆粉制备方法